Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Depressive symptoms tied to hearing impairments

22 Dec 2019

Hearing impairment appears to increase the likelihood of developing depressive symptoms, a recent study has shown.

Researchers conducted a prospective, community-based cohort study on 7,591 participants aged 50–75 years (63 percent male). Hearing impairment was measured upon recruitment and through audiometry testing; it was defined as having a pure tone average >25 db in the better ear. Incident depressive symptoms were detected using the 13-item Questionnaire of Depression, 2nd version.

After standardization against the European population, the prevalence of hearing impairment at baseline was 16.4 percent. These participants tended to be older and were more likely to be male and have comorbidities, such as hypertension, diabetes and cardiovascular disease.

A total of 479 participants developed depressive symptoms, resulting in an incidence rate of 6.3 percent. The frequency of incident depressive symptoms was higher among those with baseline hearing impairment (8.5 percent vs 5.9 percent).

After adjusting for age and sex, baseline hearing impairment emerged as a significant risk factor for developing depressive symptoms (odds ratio [OR], 1.46, 95 percent confidence interval [CI], 1.14–1.86). This remained true even after controlling for more confounders, such as physical activity, body mass index and comorbidities (OR, 1.36, 1.06–1.73). The findings were robust to sensitivity analyses.

“Future studies should evaluate whether the treatment of hearing impairment might delay or prevent depressive symptoms onset,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.